|
Safety and Efficacy of INGAP-Peptide in Patients with Type 2 Diabetes Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Safety and Efficacy of INGAP-Peptide in Patients with Type 2 Diabetes conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Safety and Efficacy of INGAP-Peptide in Patients with Type 2 Diabetes Clinical research trials and Safety and Efficacy of INGAP-Peptide in Patients with Type 2 Diabetes health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Safety and Efficacy of INGAP-Peptide in Patients with Type 2 Diabetes. Safety and Efficacy of INGAP-Peptide in Patients with Type 2 Diabetes Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Safety and Efficacy of INGAP-Peptide in Patients with Type 2 Diabetes clinical trial. Test subjects typically receive the most expert healthcare available for their Safety and Efficacy of INGAP-Peptide in Patients with Type 2 Diabetes condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Safety and Efficacy of INGAP-Peptide in Patients with Type 2 Diabetes  Safety and Efficacy of INGAP-Peptide in Patients with Type 2 Diabetes
Safety and Efficacy of INGAP-Peptide in Patients with Type 2 Diabetes
For Condition: Diabetes Mellitus, Non-Insulin-Dependent
Status: Completed
Sponsor(s): Procter & Gamble Pharmaceuticals ,
Synopsis: Insulin is a chemical that the body needs in order to use or store sugar. It is made by a type of cell called a beta cell which resides in an organ known as the pancreas. Type 2 diabetes is a disease where the beta cells are unable to meet a peson's insulin needs. Sugar levels rise in the blood as a result. INGAP-Peptide is being tested to attempt to create new beta cells in the pancreas, and to improve the ability to produce insulin in type 2 diabetic patients.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 35 Years/70 Years
Genders: Both
Protocol Entry Criteria: - Age 35-70 - Using >20 Units of insulin per day - HbA1c from 6.5% to 10% - No islet antibodies - Otherwise healthy
Total Enrollment:
Location and Contact Information:
Clinical Research Institute of Southern Oregon
Medforo, Oregon, 97504
United States
VA Hospital UCSD
San Diego, California, 92161
United States
University of Texas Health Science Center - Texas Diabetes Institute
San Antonio, Texas, 78207
United States
Diabetes and Endocrine Associates
La Jolla, California, 92037
United States
MedStar Clinical Research Center
Washington D.C., District of Columbia, 20003
United States
Diablo Clinical Research
Walnut Creek, California, 94598
United States
Future Care Studies
Springfield, Massachusetts, 01107
United States
Mountain View Clinical Research
Greer, South Carolina, 29651
United States
DGD Research Associates
San Antonio, Texas, 78229
United States
Piedmont Medical Group
Winston Salem, North Carolina, 27103
United States
Diabetes-Endocrinology Center of WNY
Buffalo, New York, 14209
United States
Mercury Street Medical
Butte, Montana, 59701
United States
UNC Diabetes Care Center
Durham, North Carolina, 27713
United States
Dallas Diabetes and Endocrine Center
Dallas, Texas, 75230
United States
Longmont Medical Research Network
Longmont, Colorado, 80501
United States
Charlottesville Medical Research
Charlottesville, Virginia, 22911
United States
Additional Information:
Study ID Numbers: 2003069;
Study Start Date:
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00071422
Other Diabetes Mellitus, Non-Insulin-Dependent Studies:
1. An evaluation of an oral antidiabetic agent for the treatment of type 2 diabetes
2. A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 Diabetes
3. The ORIGIN Trial (Outcome Reduction with Initial Glargine Intervention)
4. Evaluation of an Orally Administered Medication When Taken in Conjunction with Pramlintide
5. A Research Study to determine the safety and efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents with Type 2 Diabetes.
Related Studies:
Other Diabetes Mellitus, Non-Insulin-Dependent Clinical Trials
Other Montana Clinical Trials
Other Butte Clinical Trials
Safety and Efficacy of INGAP-Peptide in Patients with Type 2 Diabetes
|
|
|
|
|
|
|
|
